{"id":63830,"date":"2026-04-23T22:02:42","date_gmt":"2026-04-23T14:02:42","guid":{"rendered":"https:\/\/flcube.com\/?p=63830"},"modified":"2026-04-23T22:02:44","modified_gmt":"2026-04-23T14:02:44","slug":"boston-scientific-reports-strong-q1-2026-results-with-9-4-net-sales-growth-cardiovascular-segment-leads-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63830","title":{"rendered":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance"},"content":{"rendered":"\n<p><strong>Boston Scientific Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/BSX:NYSE\">NYSE: BSX<\/a>)<\/strong> has released its <strong>first quarter 2026 financial results<\/strong>, reporting <strong>group net sales of $5.203 billion<\/strong>, representing a <strong>9.4% year-over-year (YOY) increase<\/strong>. The company&#8217;s <strong>Cardiovascular segment<\/strong> drove exceptional performance with <strong>$3.5 billion in revenue<\/strong> (up 11.2%), while the <strong>MedSurg segment<\/strong> contributed <strong>$1.7 billion<\/strong> (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of <strong>6.5% to 8%<\/strong> compared to 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Net Sales<\/strong><\/td><td>$5.203 billion<\/td><td>+9.4%<\/td><\/tr><tr><td><strong>Cardiovascular Segment<\/strong><\/td><td>$3.5 billion<\/td><td>+11.2%<\/td><\/tr><tr><td><strong>MedSurg Segment<\/strong><\/td><td>$1.7 billion<\/td><td>+5.7%<\/td><\/tr><tr><td><strong>U.S. Sales<\/strong><\/td><td>$3.28 billion<\/td><td>+10.9%<\/td><\/tr><tr><td><strong>EMEA Sales<\/strong><\/td><td>$932 million<\/td><td>+1.2%<\/td><\/tr><tr><td><strong>APAC Sales<\/strong><\/td><td>$803 million<\/td><td>+12.0%<\/td><\/tr><tr><td><strong>LACA Sales<\/strong><\/td><td>$185 million<\/td><td>+12.0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-segment-performance-analysis\">Segment Performance Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Leadership:<\/strong> The <strong>$3.5 billion Cardiovascular segment<\/strong> (67% of total revenue) demonstrated robust <strong>11.2% growth<\/strong>, driven by strong demand for structural heart, electrophysiology, and peripheral interventions products<\/li>\n\n\n\n<li><strong>MedSurg Stability:<\/strong> The <strong>$1.7 billion MedSurg segment<\/strong> (33% of total revenue) delivered solid <strong>5.7% growth<\/strong>, supported by endoscopy and urology product portfolios<\/li>\n\n\n\n<li><strong>Geographic Diversification:<\/strong> All regions posted positive growth, with <strong>APAC and LACA leading at 12% each<\/strong>, while the <strong>U.S. market<\/strong> (63% of total sales) showed strong <strong>10.9% growth<\/strong><\/li>\n\n\n\n<li><strong>EMEA Recovery:<\/strong> <strong>Europe, Middle East, and Africa (EMEA)<\/strong> reported modest <strong>1.2% growth<\/strong>, reflecting ongoing market normalization following pandemic-related disruptions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-market-assessment\">Regional Market Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q1 2026 Sales<\/th><th>YOY Growth<\/th><th>Strategic Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>$3.28 billion<\/td><td>+10.9%<\/td><td>Core market strength; innovation adoption driving premium product mix<\/td><\/tr><tr><td><strong>EMEA<\/strong><\/td><td>$932 million<\/td><td>+1.2%<\/td><td>Gradual recovery; pricing pressures partially offset volume gains<\/td><\/tr><tr><td><strong>Asia-Pacific<\/strong><\/td><td>$803 million<\/td><td>+12.0%<\/td><td>Strong growth in China, Japan, and emerging APAC markets<\/td><\/tr><tr><td><strong>Latin America &amp; Canada<\/strong><\/td><td>$185 million<\/td><td>+12.0%<\/td><td>Robust procedure volumes and expanding market access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-guidance\">Forward-Looking Guidance<\/h2>\n\n\n\n<p>Boston Scientific has updated its <strong>full-year 2026 outlook<\/strong>, now expecting:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Net sales growth of 6.5% to 8%<\/strong> compared to 2025<\/li>\n\n\n\n<li><strong>Continued Cardiovascular segment leadership<\/strong> with double-digit growth trajectory<\/li>\n\n\n\n<li><strong>MedSurg segment acceleration<\/strong> in second half 2026 driven by new product launches<\/li>\n\n\n\n<li><strong>Margin expansion<\/strong> through operational efficiency initiatives and favorable product mix<\/li>\n\n\n\n<li><strong>Strategic investments<\/strong> in R&amp;D and commercial infrastructure to support long-term growth<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>The Q1 2026 results demonstrate Boston Scientific&#8217;s successful execution of its strategic priorities, with balanced growth across segments and geographies. The <strong>Cardiovascular segment&#8217;s 11.2% growth<\/strong> validates the company&#8217;s innovation pipeline and market leadership in high-growth therapeutic areas.<\/p>\n\n\n\n<p>The <strong>strong U.S. performance<\/strong> (10.9% growth) reflects successful commercial execution and physician adoption of next-generation technologies. Meanwhile, <strong>APAC and LACA&#8217;s 12% growth rates<\/strong> highlight the company&#8217;s effective international expansion strategy and growing presence in emerging markets.<\/p>\n\n\n\n<p>The modest <strong>1.2% growth in EMEA<\/strong> suggests ongoing challenges in European healthcare systems, though the positive trajectory indicates gradual recovery. Boston Scientific&#8217;s diversified geographic footprint provides resilience against regional market fluctuations.<\/p>\n\n\n\n<p>The updated full-year guidance of <strong>6.5% to 8% growth<\/strong> represents a confident outlook, supported by strong first-quarter momentum, robust procedure volumes, and a favorable innovation pipeline across both major business segments.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, market growth, and strategic initiatives. Actual results may differ due to competitive dynamics, regulatory changes, economic conditions, and other risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/q1-2026-foh.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of q1-2026-foh.\"><\/object><a id=\"wp-block-file--media-43719b05-0492-4db6-9d97-c32d393a7813\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/q1-2026-foh.pdf\">q1-2026-foh<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/q1-2026-foh.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-43719b05-0492-4db6-9d97-c32d393a7813\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[315,27,1160],"class_list":["post-63830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boston-scientific","tag-finanical-reports","tag-nyse-bsx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company&#039;s Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63830\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance\" \/>\n<meta property=\"og:description\" content=\"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company&#039;s Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63830\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T14:02:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T14:02:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance\",\"datePublished\":\"2026-04-23T14:02:42+00:00\",\"dateModified\":\"2026-04-23T14:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2305.webp\",\"keywords\":[\"Boston Scientific\",\"Finanical Reports\",\"NYSE: BSX\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63830#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63830\",\"name\":\"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2305.webp\",\"datePublished\":\"2026-04-23T14:02:42+00:00\",\"dateModified\":\"2026-04-23T14:02:44+00:00\",\"description\":\"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company's Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63830\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63830#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance - Insight, China&#039;s Pharmaceutical Industry","description":"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company's Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63830","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance","og_description":"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company's Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.","og_url":"https:\/\/flcube.com\/?p=63830","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T14:02:42+00:00","article_modified_time":"2026-04-23T14:02:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63830#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63830"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance","datePublished":"2026-04-23T14:02:42+00:00","dateModified":"2026-04-23T14:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63830"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63830#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","keywords":["Boston Scientific","Finanical Reports","NYSE: BSX"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63830#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63830","url":"https:\/\/flcube.com\/?p=63830","name":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63830#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63830#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","datePublished":"2026-04-23T14:02:42+00:00","dateModified":"2026-04-23T14:02:44+00:00","description":"Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group net sales of $5.203 billion, representing a 9.4% year-over-year (YOY) increase. The company's Cardiovascular segment drove exceptional performance with $3.5 billion in revenue (up 11.2%), while the MedSurg segment contributed $1.7 billion (up 5.7%). Boston Scientific also raised its full-year 2026 guidance, now expecting net sales growth of 6.5% to 8% compared to 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63830#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63830"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63830#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","width":1080,"height":608,"caption":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63830#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63830"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63830\/revisions"}],"predecessor-version":[{"id":63833,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63830\/revisions\/63833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63832"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}